Abstract
Carbohydrate antigen 19-9 (CA 19-9) is one of the most widespread tumor markers used in the diagnosis and management of patients with pancreatic cancer. Use of CA 19-9 as a screening tool in asymptomatic patients is not currently recommended in clinical practice due to its poor predictive value. Elevated CA 19-9 levels in patients presenting with a pancreatic mass are highly predictive of pancreatic adenocarcinoma and pre-treatment CA 19-9 levels are widely used in predicting resectability and overall survival although there is no consensus regarding optimal cut-off values. The most established use of CA 19-9 levels is in prognosticating survival and recurrence following surgical resection. In recent years, monitoring of CA 19-9 following neoadjuvant chemotherapy has demonstrated value in determining response to treatment and predicting recurrence as well. CA 19-9 continues to be used as a surrogate marker in new experimental therapies such as adjuvant surgery and irreversible electroporation.
| Original language | English (US) |
|---|---|
| Title of host publication | Pancreatic Cancer |
| Subtitle of host publication | A Multidisciplinary Approach |
| Publisher | Springer International Publishing |
| Pages | 91-94 |
| Number of pages | 4 |
| ISBN (Electronic) | 9783031057243 |
| ISBN (Print) | 9783031057236 |
| DOIs | |
| State | Published - Oct 22 2022 |
Keywords
- CA 19-9
- Carbohydrate antigen 19-9
- Diagnosis
- Management
- Pancreatic adenocarcinoma
- Prognostication
- Recurrence
- Tumor marker
ASJC Scopus subject areas
- General Medicine